LACTB2

Across TCGA pan-cancer cohorts, LACTB2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LACTB2 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LACTB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LACTB2 expression acts as an unfavorable survival marker.

BLCA, LUSC, and LUAD are the cancer types where LACTB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.188	0.654	.015	9	view →
LUSC	OS	Median	All	0.022	0.762	<.001	6	view →
LUAD	DFS	Median	All	0.605	0.814	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LACTB2–BLCA (OS)

Open the BLCA breakdown →